Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial
Objective We report post hoc analyses of efficacy with first-line avelumab plus axitinib or sunitinib according to baseline neutrophil-to-eosinophil ratio (NER) in patients with advanced renal cell carcinoma (aRCC) from the JAVELIN Renal 101 phase 3 trial.Methods and analysis Progression-free surviv...
Saved in:
| Main Authors: | Brian Rini, Mariangela Mariani, Alessandra di Pietro, Paul Nathan, Christian Kollmannsberger, Marc-Oliver Grimm, Martin H Voss, Bradley A McGregor, Mehmet A Bilen, Yoshihiko Tomita, Bo Huang, Robert Amezquita, Matthew Tucker, Yu-Wei Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | BMJ Oncology |
| Online Access: | https://bmjoncology.bmj.com/content/3/1/e000181.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Case of Immune-Related Adverse Events, Including Myasthenia Gravis, Myositis, and Myocarditis, during Avelumab and Axitinib Combination Therapy
by: Jurii Karibe, et al.
Published: (2025-04-01) -
Renal Soluble Guanylate Cyclase Is Downregulated in Sunitinib‐Induced Hypertension
by: Jeannine Witte, et al.
Published: (2018-09-01) -
Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial
by: Nicolas Penel, et al.
Published: (2021-10-01) -
A Rare Case of Sunitinib-Induced Rhabdomyolysis in Renal Cell Carcinoma
by: Andrew D. Liman, et al.
Published: (2018-01-01) -
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
by: Bart Neyns, et al.
Published: (2020-10-01)